[go: up one dir, main page]

PE20071253A1 - DERIVADOS DE PIRIDIN-3-AMINA COMO INHIBIDORES DE LA PROTEINA-QUINASA ACTIVADA POR MITOGENOS p38 - Google Patents

DERIVADOS DE PIRIDIN-3-AMINA COMO INHIBIDORES DE LA PROTEINA-QUINASA ACTIVADA POR MITOGENOS p38

Info

Publication number
PE20071253A1
PE20071253A1 PE2007000179A PE2007000179A PE20071253A1 PE 20071253 A1 PE20071253 A1 PE 20071253A1 PE 2007000179 A PE2007000179 A PE 2007000179A PE 2007000179 A PE2007000179 A PE 2007000179A PE 20071253 A1 PE20071253 A1 PE 20071253A1
Authority
PE
Peru
Prior art keywords
pyridin
mitogenes
inhibitors
protein
methanone
Prior art date
Application number
PE2007000179A
Other languages
English (en)
Inventor
Juan Bernart Vidal
Javolyes Juan Francisco Caturla
Amador Wenceslao Lumeras
Gispert Laura Vidal
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of PE20071253A1 publication Critical patent/PE20071253A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIRIDIN-3-AMINA DE FORMULA (I), EN DONDE R1 ES ARILO O HETEROARILO, MONO O POLICICLICO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C6), ENTRE OTROS; R2 ES UN GRUPO CICLICO DE 5 A 10 MIEMBROS OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), HIDROXI, CF3, -X-(CH2)n-Y-G, ENTRE OTROS; x ES UN VALOR ENTRE CERO O UNO. SON SELECCIONADOS: (3-AMINO-2-FENILPIRIDIN-4-IL)(FENIL)METANONA, (3-AMINO-1-OXIDO-2-FENILPIRIDIN-4-IL)(FENIL)METANONA, [3-AMINO-2-(4-CLOROFENIL)PIRIDIN-4-IL](FENIL)METANONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA-QUINASA ACTIVADA POR MITOGENOS p38 Y SON UTILES PARA TRATAMIENTO DE ARTRITIS REUMATOIDE, LESION POR ISQUEMIA-REPERFUSION, SINDROME CORONARIO AGUDO PSORIASIS, ATEROSCLEROSIS, ENTRE OTRAS
PE2007000179A 2006-02-20 2007-02-16 DERIVADOS DE PIRIDIN-3-AMINA COMO INHIBIDORES DE LA PROTEINA-QUINASA ACTIVADA POR MITOGENOS p38 PE20071253A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200600396A ES2303758B1 (es) 2006-02-20 2006-02-20 Nuevos derivados de piridin-3-amina.

Publications (1)

Publication Number Publication Date
PE20071253A1 true PE20071253A1 (es) 2008-01-14

Family

ID=36061581

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000179A PE20071253A1 (es) 2006-02-20 2007-02-16 DERIVADOS DE PIRIDIN-3-AMINA COMO INHIBIDORES DE LA PROTEINA-QUINASA ACTIVADA POR MITOGENOS p38

Country Status (9)

Country Link
US (1) US20110098298A1 (es)
EP (1) EP1987005A2 (es)
JP (1) JP2009527515A (es)
CN (1) CN101395136A (es)
AR (1) AR059556A1 (es)
ES (1) ES2303758B1 (es)
PE (1) PE20071253A1 (es)
TW (1) TW200804285A (es)
WO (1) WO2007096072A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077262A4 (en) * 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
US20110039846A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US8481569B2 (en) * 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
WO2013033085A1 (en) * 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9428464B2 (en) * 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338286A1 (en) * 2001-04-10 2002-10-28 Leo Pharma A/S Novel aminophenyl ketone derivatives
CN1774250A (zh) * 2003-04-16 2006-05-17 霍夫曼-拉罗奇有限公司 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6－(苯氧基)－吡啶并[3,4－d]嘧啶－2－基)－胺衍生物
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
AR059556A1 (es) 2008-04-09
WO2007096072A2 (en) 2007-08-30
CN101395136A (zh) 2009-03-25
ES2303758A1 (es) 2008-08-16
US20110098298A1 (en) 2011-04-28
ES2303758B1 (es) 2009-08-13
JP2009527515A (ja) 2009-07-30
TW200804285A (en) 2008-01-16
WO2007096072A3 (en) 2007-10-11
EP1987005A2 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
PE20071253A1 (es) DERIVADOS DE PIRIDIN-3-AMINA COMO INHIBIDORES DE LA PROTEINA-QUINASA ACTIVADA POR MITOGENOS p38
PE20191817A1 (es) Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
MX2013004242A (es) Sulfonamidas nematocidas.
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
PE20091414A1 (es) FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS
PE20140011A1 (es) Compuestos y composiciones novedosos para la inhibicion de nampt
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
EA201201052A1 (ru) Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk
NO20055688L (no) Organiske forbindelser
PE20080205A1 (es) DERIVADOS DE PIRAZOLOPIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSIN QUINASA Tie2
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR071619A1 (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.
AR064198A1 (es) Piperidinilamino piridazinas como antagonistas del receptor de dopamina 2 de rapida disociacion. procesos de obtencion y composiciones farmaceuticas
AR066956A1 (es) Derivados de [1,10]-fenantrolina, composiciones farmaceuticas que los contienen, metodo de preparacion y uso para el tratamiento de enfermedades neurodegenerativas o hematologicas.
BRPI0617918B8 (pt) compostos de fórmula (i) e seu uso, medicamentos e composição farmacêutica
PE20081376A1 (es) Derivados de pirrolizina, indolizina y quinolizina, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FD Application declared void or lapsed